Font Size: a A A

The Relationship Between The Expression Of MMP-2,MMP-9,TIMP-1 And TIMP-2 And Peritoneal Fibrosis Before And After Peritoneal Dialysis

Posted on:2020-02-29Degree:MasterType:Thesis
Country:ChinaCandidate:Y ShiFull Text:PDF
GTID:2404330602955434Subject:Immunology
Abstract/Summary:PDF Full Text Request
Peritoneal dialysis is a common alternative to saving the lives of patients with end-stage renal disease.However,after peritoneal dialysis,due to dialysis,peritoneal inflammation is easily complicated by peritoneal dialysis peritonitis.The incidence of the disease is very high.However,there are no effective methods to inhibit peritonitis,and how to predict peritonitis in advance will have important significance in increasing the therapeutic effect of peritoneal dialysis and delaying complications.Matrix metalloproteinases dynamically adjust the fibrosis process of organs or tissues.However,it is rare to report the relationship between the relevant changes of MMPs/TIMPs and peritonitis in patients with uremia after peritoneal dialysis treatment.In this paper,patients with clinical uremia undergoing peritoneal dialysis were observed to observe the changes of MMP-2,MMP-9,TIMP-1 and TIMP-2 in peritoneal flushing after treatment with the same peritoneal dialysis program.In order to analyze the relationship between the expression of MMP-2,MMP-9,TIMP-1 and TIMP-2 and peritonitis in peritoneal flushing after peritoneal dialysis in patients with uremia,To find out the incidence of peritoneal dialysis fibrosis and increase the survival rate of uremia patients,the basic research data are laid down.In order to reveal the cellular biological causes of peritoneal fibrosis complications in uremic patients after peritoneal dialysis,and to lay a foundation for finding out the incidence of inhibiting peritoneal fibrosis in peritoneal dialysis and increasing the survival rate of uremic patients.Fifty-five uremic patients who had received regular peritoneal dialysis for a long time were collected.The same dialysate was used in each peritoneal dialysis.Each dialysis lasted for 4 hours.Fifty-five patients underwent 10 dialysis examinations.Western Blot and ELISA were used to analyze the changes of MMP-2,MMP-9,the TIMP-1 and TIMP-2 in peritoneal lavage fluid before and after peritoneal dialysis.Peritonitis was diagnosed before and after treatment,and the content of hydroxyproline in peritoneal lavagefluid was detected.Results shown that the relative absorbance of MMP-2 and MMP-9 in peritoneal lavage fluid after peritoneal dialysis was 0.61±0.15 and 0.63±0.07 times before peritoneal dialysis,respectively,with significant difference(P<0.01).Compared with that before peritoneal dialysis,the relative absorbance of TIMP-1 and TIMP-2in peritoneal lavage fluid after peritoneal dialysis increased by 1.31±0.82 and2.75±0.12 times respectively,with significant difference(P<0.01).Compared with pre-dialysis treatment,the contents of MMP-2 and MMP-9 protein decreased significantly after dialysis treatment,and there were significant differences(P<0.01);compared with pre-dialysis treatment,the contents of TIMP-1 and TIMP-2protein increased significantly after dialysis treatment,and there were significant differences(P< 0.01).The ratios of MMP-2/TIMP-2 and MMP-9/TIMP-1 were less than 1:1,and there were significant differences between the ratios before and after peritoneal dialysis(P<0.01).In addition,the complication rate of peritonitis in patients with uremia after peritoneal dialysis was 49(89.99%)compared with that in3(5.45%)patients before peritoneal dialysis(P< 0.01).Conclusions:(1)The contents of MMP-2 and MMP-9 in peritoneal lavage fluid decreased after peritoneal dialysis.The contents of TIMP-2 and TIMP-1 in peritoneal lavage fluid increased significantly after peritoneal dialysis.(2)The decrease of MMP-2/TIMP-2 and MMP-9/TIMP-1 ratio may be the cause of peritoneal fibrosis in uremic patients after peritoneal dialysis.
Keywords/Search Tags:Uremia, Peritoneal dialysis, Peritonitis, Peritoneal fibrosis, Matrix metalloproteinase-2, Matrix metalloproteinase-9, Matrix metalloproteinase inhibitor-2, Matrix metalloproteinase inhibitor-1
PDF Full Text Request
Related items